BioLife Solutions Toekomstige groei

Future criteriumcontroles 4/6

BioLife Solutions zal naar verwachting groeien in winst en omzet met respectievelijk 70.7% en 14.4% per jaar. De winst per aandeel zal naar verwachting groeien met 71.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -4% zijn.

Belangrijke informatie

70.7%

Groei van de winst

71.3%

Groei van de winst per aandeel

Life Sciences winstgroei	18.3%
Inkomstengroei	14.4%
Toekomstig rendement op eigen vermogen	-4.0%
Dekking van analisten	Good
Laatst bijgewerkt	15 Oct 2024

Recente toekomstige groei-updates

Recent updates

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Aug 30

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

Aug 14

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10

BioLife: What The Future Holds

Oct 19

BioLife Solutions COO Roderick de Greef to retire

Oct 03

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Sep 27

Winst- en omzetgroeiprognoses

NasdaqCM:BLFS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	151	6	11	25	5
12/31/2025	119	-12	-6	19	9
12/31/2024	110	-26	-7	8	10
6/30/2024	140	-64	-8	0	N/A
3/31/2024	141	-62	-22	-14	N/A
12/31/2023	143	-66	-24	-12	N/A
9/30/2023	136	-93	-22	-7	N/A
6/30/2023	143	-74	-17	-1	N/A
3/31/2023	155	-141	-19	-3	N/A
12/31/2022	162	-140	-22	-8	N/A
9/30/2022	155	-106	-28	-17	N/A
6/30/2022	148	-96	-27	-17	N/A
3/31/2022	139	-15	-27	-14	N/A
12/31/2021	119	-9	-19	-5	N/A
9/30/2021	97	5	-19	-2	N/A
6/30/2021	74	4	-19	-4	N/A
3/31/2021	53	-20	-3	8	N/A
12/31/2020	48	2	-1	7	N/A
9/30/2020	42	7	0	3	N/A
6/30/2020	37	16	1	5	N/A
3/31/2020	34	39	-3	1	N/A
12/31/2019	27	-2	-1	1	N/A
9/30/2019	25	-32	2	3	N/A
6/30/2019	23	-39	2	2	N/A
3/31/2019	22	-44	2	3	N/A
12/31/2018	20	-25	2	2	N/A
9/30/2018	17	1	2	3	N/A
6/30/2018	15	0	2	2	N/A
3/31/2018	12	-2	N/A	1	N/A
12/31/2017	11	-3	N/A	1	N/A
9/30/2017	10	-5	N/A	-1	N/A
6/30/2017	9	-6	N/A	-2	N/A
3/31/2017	9	-7	N/A	-3	N/A
12/31/2016	8	-7	N/A	-4	N/A
9/30/2016	8	-5	N/A	-5	N/A
6/30/2016	7	-5	N/A	-5	N/A
3/31/2016	7	-4	N/A	-5	N/A
12/31/2015	6	-4	N/A	-5	N/A
9/30/2015	6	-4	N/A	-4	N/A
6/30/2015	6	-4	N/A	-4	N/A
3/31/2015	6	-4	N/A	-4	N/A
12/31/2014	6	-3	N/A	-3	N/A
9/30/2014	7	-3	N/A	-2	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/31/2014	9	-2	N/A	-1	N/A
12/31/2013	9	-1	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat BLFS de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat BLFS de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat BLFS binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van BLFS ( 14.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van BLFS ( 14.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat BLFS binnen 3 jaar verliesgevend zal zijn.

BioLife Solutions Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

Price target increased by 7.4% to US$27.33

Price target increased by 7.2% to US$26.56

BioLife Solutions, Inc. Updates Revenue Guidance for the Year 2024

Consensus estimates of losses per share improve by 47%

No longer forecast to breakeven

Recent updates

BioLife Solutions, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Chairman of Scientific Advisory Board exercised options and sold US$423k worth of stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Now 25% undervalued

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Now 22% undervalued

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.4% to US$27.33

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.2% to US$26.56

BioLife Solutions, Inc. Updates Revenue Guidance for the Year 2024

BioLife Solutions, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 22% undervalued

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver

Consensus estimates of losses per share improve by 47%

No longer forecast to breakeven

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Price target increased by 7.8% to US$23.88

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 1Q 2023)

BioLife Solutions, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast breakeven date pushed back to 2026

An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $2.6 million.

An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS).

Lead Director notifies of intention to sell stock

Lead Director recently sold US$190k worth of stock

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Full year 2023 earnings: EPS exceeds analyst expectations

Forecast breakeven date pushed back to 2026

BioLife Solutions, Inc. to Report Q4, 2023 Results on Feb 29, 2024

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Consensus EPS estimates fall by 75%

Third quarter 2023 earnings: EPS misses analyst expectations

BioLife Solutions, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Consensus revenue estimates decrease by 18%, EPS upgraded

Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Price target decreased by 17% to US$25.14

BioLife Solutions, Inc. to Report Q2, 2023 Results on Aug 08, 2023

BioLife Solutions, Inc., Annual General Meeting, Jul 21, 2023

BioLife Solutions, Inc. announced delayed 10-Q filing

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Chairman of Scientific Advisory Board exercised options and sold US$346k worth of stock

Chairman & CEO recently sold US$64k worth of stock

Chairman of Scientific Advisory Board exercised options and sold US$391k worth of stock

Consensus EPS estimates fall by 62%

Full year 2022 earnings: EPS misses analyst expectations

Chairman & CEO recently sold US$98k worth of stock

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Chairman of Scientific Advisory Board exercised options and sold US$436k worth of stock

Director recently sold US$88k worth of stock

Director recently sold US$88k worth of stock

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Chairman of Scientific Advisory Board exercised options and sold US$321k worth of stock

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Now 20% undervalued after recent price drop